Omalizumab biosimilar (Fountain BioPharma)

奥马佐单抗生物类似药 (Fountain BioPharma)

Report date: 2022/07/15 15:12:30

Base Information

Drug NameOmalizumab biosimilar (Fountain BioPharma)

Drug Alias Name奥玛利珠单抗生物仿制药 (Fountain BioPharma)奥马佐单抗生物仿制药 (Fountain BioPharma)奥马珠单抗生物仿制药 (Fountain BioPharma)重组抗IgE单克隆抗体 (Fountain BioPharma)FB-317

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar

Mechanisms of ActionImmunoglobulin E inhibitors

TargetsImmunoglobulin E

Therapy Area/IndicationsUrticariaAsthma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesAcademia Sinica

China Registration ClassN/A

Inactive CompaniesN/A

Active IndicationsUrticariaAsthma

Inactive IndicationsN/A

ATC CodeR03DX05